Johnson & Johnson (JNJ)
After hours:
| Previous close | 157.09 |
| Open | 157.91 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1300 |
| Day's range | 157.59 - 159.67 |
| 52-week range | 148.51 - 179.92 |
| Volume | |
| Avg. volume | 7,119,796 |
| Market cap | 419.584B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 23.82 |
| EPS (TTM) | 6.69 |
| Earnings date | 25 Jan 2022 |
| Forward dividend & yield | 4.24 (2.70%) |
| Ex-dividend date | 22 Nov 2021 |
| 1y target est | 187.76 |
- Motley Fool
Why Moderna Is the Biggest Winner From COVID Boosters So Far
Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.
- Motley Fool
2 Robinhood Stocks to Buy and Hold for 10 Years
Robinhood Markets was one of the pioneers of the commission-free investing model that is now so common among online brokers. At the same time, Robinhood has its share of detractors. Johnson & Johnson (NYSE: JNJ) is one of the largest healthcare companies in the world by market cap, but this juggernaut is about to get smaller.
- Motley Fool
Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?
Bristol Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) compete against each other in the marketplace every day. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for this experimental drug. Keith Speights: Bristol Myers Squibb and Johnson & Johnson compete head-to-head in the blood thinner market.
